EUVIMEDSkopri EUVIMED
Open access · CC BY 4.0

Challenges and advances of immune checkpoint therapy

Lingyu Li, Yingli Sun

Clinical and Translational Discovery · 2024-12 · 4 (6)

DOI: 10.1002/ctd2.70001 ↗

At a glance

Journal article in Clinical and Translational Discovery, published online on 2024-11-04. Written by Lingyu Li and 1 co-authors. Cited 6 times so far (Crossref); 215 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Natural Science Foundation of China.

AstrattDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background and Objectives Immuno‐checkpoint therapy (ICT) significantly alters the clinical course of cancer patients, providing long‐lasting clinical benefits and offering the potential for cure to some patients. However, response rates for different tumour types vary, and predictive biomarkers are needed to enhance patient selection for the purpose of optimising effectiveness and reducing toxicity. This has driven efforts to decipher the immune and non‐immune factors that regulate ICT response. Main Content This review offers a thorough examination of the advantages and future challenges of immune checkpoint inhibitors in cancer therapy. Additionally, we explore ongoing efforts to address current challenges, such as guiding subsequent clinical trials, developing ICT combination therapy strategies and utilising epigenetics to enhance clinical efficacy. Conclusion and Perspectives Despite significant progress, ICT faces challenges including immune‐related adverse events (irAEs) and resistance mechanisms. Ongoing research focuses on developing novel biomarkers, combination therapies, and epigenetic strategies to improve the efficacy and safety of ICT for cancer patients worldwide. Future studies are required to validate these findings across different tumor types and treatment settings.

Funding

  • National Natural Science Foundation of China

Cite

APA

Li, L., & Sun, Y. (2024). Challenges and advances of immune checkpoint therapy. Clinical and Translational Discovery, 4(6). https://doi.org/10.1002/ctd2.70001

Vancouver

Li L, Sun Y. Challenges and advances of immune checkpoint therapy. Clinical and Translational Discovery. 2024;4(6). doi:10.1002/ctd2.70001

BibTeX
@article{Li2024,
  author = {Li, Lingyu and Sun, Yingli},
  title = {Challenges and advances of immune checkpoint therapy},
  journal = {Clinical and Translational Discovery},
  year = {2024},
  volume = {4},
  number = {6},
  doi = {10.1002/ctd2.70001}
}
Start for free →